Leerink Partnrs Brokers Lift Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Leerink Partnrs upped their Q2 2026 EPS estimates for Ironwood Pharmaceuticals in a research note issued on Monday, November 10th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings of $0.13 per share for the quarter, up from their prior estimate of $0.11. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2026 earnings at $0.15 EPS and Q4 2026 earnings at $0.25 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. The business had revenue of $122.06 million for the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other analysts have also recently weighed in on IRWD. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wells Fargo & Company boosted their price target on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research report on Tuesday. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.34.

Ironwood Pharmaceuticals Price Performance

IRWD opened at $2.89 on Wednesday. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.13. The company’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $1.07. The firm has a market capitalization of $469.43 million, a price-to-earnings ratio of -57.79 and a beta of 0.37.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers increased its stake in Ironwood Pharmaceuticals by 3.5% during the 3rd quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 7,611 shares in the last quarter. Savant Capital LLC lifted its position in Ironwood Pharmaceuticals by 15.4% in the 3rd quarter. Savant Capital LLC now owns 309,069 shares of the biotechnology company’s stock valued at $405,000 after acquiring an additional 41,293 shares in the last quarter. State of Wyoming lifted its position in Ironwood Pharmaceuticals by 76.2% in the 3rd quarter. State of Wyoming now owns 362,407 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 156,763 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in Ironwood Pharmaceuticals by 43.5% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 72,706 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 22,029 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in Ironwood Pharmaceuticals by 23.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 154,388 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 28,928 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.